Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25937577 | 0.81 | POLB (0.33) | SCN9APOLB | |
| SCHEMBL801407 | 0.75 | VCAM1 (0.36) | ALDH1A1NPSR1LMNAMAPT | |
| SCHEMBL3225876 | 0.73 | ALDH1A1 (0.38) | CHRNB2CHRNA4ALDH1A1NPSR1LMNA | |
| SCHEMBL5942319 | 0.72 | CHRNB2 (0.41) | CHRNB2CHRNA4ALDH1A1NPSR1 | |
| SCHEMBL28890814 | 0.71 | — | — | |
| SCHEMBL28207671 | 0.70 | ALDH1A1 (0.46) | ALDH1A1POLBMAPTTDP1 | |
| SCHEMBL14720949 | 0.69 | CHRNB2 (0.45) | CHRNB2CHRNA4SCN9A | |
| SCHEMBL12225600 | 0.69 | CHRNA3 (0.41) | CHRNB2CHRNA4 | |
| SCHEMBL15918740 | 0.69 | ALDH1A1 (0.50) | CHRNB2CHRNA4ALDH1A1NPSR1LMNA | |
| SCHEMBL27919624 | 0.69 | CHRNB2 (0.43) | CHRNB2CHRNA4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455535-B2 | Heteroaryl dihydroindolones as kinase inhibitors | ALLERGAN, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110257238-A1 | Heteroaryl Dihydroindolones as Kinase Inhibitors | ALLERGAN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257238-A1 | Heteroaryl Dihydroindolones as Kinase Inhibitors | REN, JAK2, ABL1 | CHRNB2 4812/4885CHRNA4 4763/4885SCN9A 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.